eln and drug development one common platform for all€¦ · eln and drug development – one...

31
eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis Pharma AG Chemical & Analytical Development

Upload: others

Post on 29-May-2020

13 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

eLN and Drug Development –

One Common Platform for All

Dietmar Flubacher, Senior Fellow

Basel

November 04, 2016

Novartis Pharma AG

Chemical & Analytical

Development

Page 2: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Agenda

1. eLN@TRD – A Global Application

2. Different Workflows for Different Departments

3. Reports as “Official Document”

4. Structured Documentation for Further Analysis

Public2

Page 3: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

eLN@TRD – a Global Application

Public3

• eLN@TRD is used for non-GxP

documentation

• Users: > 600 users

– >500 Full access, ~100 Read Only

– Departments:

– Chemical Development (CHAD)

and Process Analytic (PA)

– Particle Engineering (PEN)

– Chemical Physical Properties (CPP)

– Pharmaceutical Development (PHAD)

– Local Supply Center (LSC, ReadOnly)

– ChemOps

– Sandoz

BaselMengeš

Hyderabad

Cambridge

Emeryville

San CarlosChangzhou

Shanghai

Page 4: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

eLN@TRD – The Setup

• Servers located in Switzerland

– Servers hosting and maintenance outsourced

– Additional Development- (as VM) and Test-System

• Main Team and PE-contacts located in Basel

– 1st level support by local SuperUsers

– 2nd level support by externals (D-ploy GmbH)

– 3rd level support by PE (located in India)

• Further Development

– 1-2 SuperUsers per functional group with Admin-Training

– Global adjustment is done by SuperUsers

Public4

Page 5: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

eLN@TRD – Growing within TRD

Public5

01.01.2010 31.10.2016

01.01.2011 01.01.2012 01.01.2013 01.01.2014 01.01.2015 01.01.2016

02.04.2012Migration to v12.1

30.06.2011 - 09.04.2012

Preparation of Migration

24.07.2012

Onboarding Formulation (PHAD)

09.03.2014

Onboarding Safety Lab

02.01.2016

Onboarding SANDOZ (Menges)

01.01.2010Full Roll-out

v11.3 eLN@TRD

17.04.2015

Roll-out eLN@TRD/Spotfire

Interface

12.08.2016

Onboarding Manufacturing

(ChemOps/MST)

28.01.2013

Onboarding Process Analytics

25.07.2014

Implementaion Equipment Management

31.01.2011

Reorganization of Users

Page 6: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Agenda

1. eLN@TRD – A Global Application

2. Different Workflows for Different Departments

3. Reports as “Official Document”

4. Structured Documentation for Further Analysis

Public6

Page 7: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Separating «Content» and «Users»

• Privileges are granted on «User Group»-

level

• Users can manage their privileges

IT-support not required for managing

access

«Content» and «Users»

Public7

Page 8: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Chemical Process Development, PEN, CPP and MST

• User based notebooks created by form tool supporting this process

• Notebooks contain only CPD-specific experiments

• Specific Notebooks for specific requirements

Pharmaceutical Development

• Notebooks based on application route and created during project setup

• Write access provided by «Project Responsible» by drag/drop to «Project members»

Process Analytics

• Notebooks are created for each year

• Word wide write-access for all PA-members

Safety Lab

• One notebook for global access, all safety related information in one source

• Notebooks contain only SafetyLab-specific experiments

The Project as Focal Point

Public8

Page 9: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Add Inn: R&D LIMS

• Synthetic Experiments ↔ Process Analytics

– 15 Methods defined (HPLC purity, GC purity, HPL Assay, GC/MS, ...)

– 2371 requests in 2015

– Problem: Sample vs. Sequence

• Synthetic Experiments ↔ Safety Lab

– 6 Methods defined (DSC, SEDEX, RADEX, ...)

– 1153 requests in 2015

Benefits:

– Planning Tool

– Traceability

– Important information is provided by request

Public9

Page 10: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Add Inn: Equipment Management

• Tracking of calibration status for all equipment used in

different departments

• Referencing and tracking of used equipment for QRA

(Quality Risk Analysis) and COI (Carry over of

Impurities)

Public10

Page 11: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Agenda

1. eLN@TRD – A Global Application

2. Different Workflows for Different Departments

3. Reports as “Official Document”

4. Structured Documentation for Further Analysis

Public11

Page 12: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Creating a Calo-report involves the

contributions of several persons

• In a classical approach, the

experiments are performed and the

report is created as separate

document

Why not using eLN@TRD as

collaboration platform and the

report is the «printout» of the

experiment

First Comment: «This will not work!»

Collaboration Within a Team

Public12

Page 13: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Sections in alignment with chapters of final Report

• RD LIMS providing full traceability of samples

Collaboration by Structured

Documentation

Public13

Page 14: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Legally relevant document stored

within eLN@TRD

• Report for distribution as PDF

with digital signature

Creating an Official Report

Public14

Page 15: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Agenda

1. eLN@TRD – A Global Application

2. Different Workflows for Different Departments

3. Reports as “Official Document”

4. Structured Documentation for Further Analysis

Public15

Page 16: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

During chemical process

development a lot of data

are generated around a

single chemical reaction.

In the past these data have

been copied/pasted from

eLN@TRD into

Excel/Word. This process is

time consuming and prone

to human error

Visualization and Analysis of Data

Public16

Page 17: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Project Scope

Public17

Scope of 1st Generation

Ease

of

Imp

lem

en

tati

on

Low

Moderate: requires alternative

DATA INPUT into eLN@TRD

Difficult: requires fundamental

changes to DATA INPUT into

eLN@TRD

Easy: data already in

structured form in eLN@TRD

MediumHigh

Yield Purity

TimesTemp.

Stoichiometry

Detailed

analytical

data

Addition

rate

Heat/cool

rate

Rest

Solvent

Page 18: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Baseline – Time Required to

Extract Data

How much time is needed to extract data into an Excel sheet?

ca. 3 minutes per experiment, ~ 10% of the data points extracted were incorrect

• Time spent on extracting data per year:

– >15’000 standard experiments per year assume 50 % used for data extraction

– >7’500 experiments used for extraction 3 min per experiment

– ~400 h/year or ~50 working days spent on extraction of data

Public18

Page 19: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Challenge: Standardization of

Input but Maintain Flexibility

• All processes are different

• The knowledge and understanding of the process is

increasing during development. Therefor different

parameters are of interest over time.

– Hard coded templates is not a solution

– Extensive drop-down menu will always not include all needs

• Version-control to reduce filters (typos, ...)

Defining master-template and use of references

Public19

Page 20: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Ranking by 8 people eachwith 3 votes

• Allocation of stickers topreferred solution(s)

• 2 strongly preferredsolutions:

Drag&Drop 9 votes

eLN Template 15 votes

• A combination of bothsolutions-transferring datadirectly from theexperimental protocol to theeLN template is veryattractive

Workshop on Input of Data

Public20

Page 21: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Defining Master-Template by users for each reaction

• Adding only References to «Template»-folder ensures only one common template for all

• Data pair «Value»/«Description» provides solution to Flexibility vs. Standardization

Defining and Use of Master

Templates

Public21

Page 22: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Inserting Data

Public22

• Transfer during write up of Protocol

Page 23: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Inserting Data

Public23

• Transfer during write up of Protocol

• Select Value to be transferred

Page 24: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Inserting Data

Public24

• Transfer during write up of Protocol

• Select Value to be transferred

Page 25: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Transfer during write up of Protocol

• Select Value to be transferred

• «Drag&Drop» value to selected field

Inserting Data

Public25

Page 26: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Transfer during write up of Protocol

• Select Value to be transferred

• «Drag&Drop» value to selected field

Inserting Data

Public26

Page 27: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• Documentation in structured way

• Time saving compared to «old» process ~90 %

• One source of data, reducing errors

Inserting Data

Public27

Page 28: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

Yield and Purity of all

Experiments

Which reagents have

been used how often and

in which experiment

Correlations between

yield/purity and any

process parameter

Visualization in Spotfire

Predefined Graphical Representations for Different Needs

Public28

Page 29: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

The Future

• Extension of Spotfire to include analytical data

• Interfacing with instruments

• Data created by CROs

• Migration

Public29

Page 30: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Novartis Pharma AG, Chemical & Analytical Development

• CHAD Synthesis/Analytics

• Bosshard, Andreas

• Cao, Yudong

• Eijgel, Andreas

• Flubacher, Dietmar

• Gerber, Gilles

• Hook, Christine

• Mathes, Christian

• Müller, Sibylle

• Naehrig, Daniel

• Richter, Yvonne

• Stierlin, Stephane

• Venturoni, Francesco

• Wicky, Regine

• Yang, Yao

• Spotfire

• Rajamani, Ramesh (NBS)

• Zünd, Gemma

• CPP

• Chang, Shelley

• Towler, Chris

• Widmer, Toni

• Zhang, Lijun

• PEN

• Hautle, Cathrine

• Meister, Tanja

• Muminovic, Jasmin

• Mut, Larissa

• Wiedmer, Alain

• Safety Lab

• Hoehn, Pascal

• Lanz, Marian

• ChemOps

– Glutz, Markus

– Koehler, Nils

– Rautenkranz, Cedric

The Team

Public30

• PHAD

• Besseyrias, Philippe

• Cherkupally, Laxman

• De Waard, Hans

• Fernandes, Patricia

• Gilardoni, Elodie

• Graner, Oliver

• Kollipara, Sivacharan

• Rogue, Christelle

• Taillemite, Julien

• Volpatti, Sophie

• Sandoz

• Crnugelj, Martin

• Plantan, Ivan

• Selic, Lovro

• 2nd Level support

• Milis, Aleksandar

• Schweikert, Martin

Page 31: eLN and Drug Development One Common Platform for All€¦ · eLN and Drug Development – One Common Platform for All Dietmar Flubacher, Senior Fellow Basel November 04, 2016 Novartis

Thank you